| Outcome Measures: |
Primary: Average Exogenous Basal Insulin Compared to Baseline (Placebo), The least squares means difference of basal exogenous insulin between treatment A and placebo and treatment B and placebo, utilized over the final ten (10) days of each treatment period, Combined Final ten days of each treatment period. Period1 (days -8 to 1)Period 2 (days 19 to 28) ,and Period 3 (days 47 to 56)|Average Exogenous Bolus Insulin Compared to Baseline (Placebo), The amount of exogenous bolus insulin utilized over the final ten (10) days of each treatment period measured in mg/dL, Combined Final ten days of treatment per treatment period (Days -8 to 1, Days 19 to 28, and Days 47 to 56)|Average Exogenous Total Insulin Compared to Baseline, The Least Squares Mean Difeerence ( (mg/dL) of total exogenous insulin (the sum of basal + bolus exogenous insulin) over the final ten (10) days of treatment., Combined Final ten days of treatment , day -8 to 1 (Period 1) Days 19 to 28 (Period 2), Days 47 to 56 (Period 3) | Secondary: Daytime Average Mean Glucose Compared to Baseline, Least Squares Mean Difference from Baseline of Daytime Average Mean Glucose over the final ten (10) days of each treatment and each treatment period as measured by CGM., Combined Study days -8 to 1 (Period 1) Days 19 to 28 (Period 2), and days 47 to 56 (Period 3)|Daytime Glucose Coefficient of Variation Compared to Baseline, Least Squares Mean Continuous Glucose Monitor (CGM) Glucose Coefficient of Variation measured over daytime hours, compared to Baseline, Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)|Daytime Low Blood Glucose Index (LBGI) Compared to Baseline, Least Squares Mean Daytime Low Blood Glucose Index (LBGI) measured over the last ten (10) days of the treatment period, compared to Baseline LBGI is a clinical scale that indicates the probability for hypoglycemia. Blood Glucose Variability is an important measure because it provides additional clarification for HbA1c value. The risk of hypglycemic events and the LBGI scale is defined as follows: Minimal Risk ( LBGI \< 1.1) Low Risk ( 1.1 \< LBGI \< 2.5) Moderate Risk (2.5 \< LBGI \< 5), HIgh Risk ( LBGI \> 5), Combined Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)
|
